Special Issue

The Advances of Cold Plasma in the Biomedicines 2.0

Message from the Guest Editor

Plasma used in industrial fields requires a vacuum state and can generate high heat. When the temperature of the plasma is less than 250 degrees Celsius, it is called low-temperature plasma. In order to be treated on human tissues, the temperature of the plasma must be less than 40 degrees Celsius. In that respect, it has recently been referred to as cold plasma. Plasma medicine, which started when cold plasma was applied to bacteria and cells, has made considerable progress over the past 20 years. The scope of plasma research has expanded from just killing pathogens and cancer cells to tissue regeneration and selective cancer cell death. In the current research climate, this Special Issue calls for advanced plasma medicine research results by not only explaining various life phenomena induced by plasma, but also cellular or histologic mechanisms. The scope of the research subject is limited to bacteria living in animals, animal cells and tissues, and biomaterials that can be inserted into the human body. Experimental papers and review papers consistent with this research topic are both eligible.

Guest Editor

Prof. Dr. Gyoocheon Kim

Department of Oral Anatomy, School of Dentistry, Pusan National University, Yangsan 50612, Korea

Deadline for manuscript submissions

closed (15 April 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/124220

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).